|
|
|
Bioinformatics -- the marriage of biology and information technology -- is changing the way scientists study disease and develop medicines, replacing hours of tedious laboratory work with a few mouse clicks.
But bioinformatics companies, which captured Wall Street's imagination in the late 1990s, are losing their luster with investors. For instance, shares of InforMax Inc., a Bethesda software maker, are trading near their all-time low. Yet Stephen E. Lincoln, InforMax's chief scientific officer, is as bullish as ever on the future of the industry. Full story can be found in the Washington Post, March 14, 2002.
Message posted by: Anthony W.I. Lo
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|